Prescient’s PTX-100 Enters Phase 2A Trial for Rare Lymphoma, Boosting ASX200 Biotech Momentum
Prescient Therapeutics (ASX: PTX) begins Phase 2A trial of PTX-100 for rare lymphoma, drug shows...
Prescient Therapeutics (ASX: PTX) begins Phase 2A trial of PTX-100 for rare lymphoma, drug shows...
Prescient Therapeutics (ASX: PTX) earlier this week began its Phase 2A clinical trial of PTX-100...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the initiation of a Phase...
Prescient Therapeutics: Shareholder Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics Ltd has kicked off its Phase 2a clinical trial evaluating PTX-100 for relapsed...
Prescient Therapeutics: Shareholder Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics (ASX: PTX) has received fast-track designation from the US Food and Drug Administration...
Prescient Therapeutics Ltd has received Fast Track Designation from the United States Food and Drug...
Prescient Therapeutics Ltd has appointed Melanie Farris as an independent non-executive director, further strengthening its...
Clinical-stage oncology company Prescient Therapeutics Ltd has opened the first clinical site for its Phase...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.